Previous Article | Next Article 
Journal of Bacteriology, May 2000, p. 2635-2638, Vol. 182, No. 9
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Site-Specific Serine Incorporation by Lif and Epr
into Positions 3 and 5 of the Staphylococcal Peptidoglycan
Interpeptide Bridge
Kerstin
Ehlert,1
Martin
Tschierske,2
Claudio
Mori,2
Werner
Schröder,1 and
Brigitte
Berger-Bächi2,*
Bayer AG, PH Research Antiinfectives I,
D-42096 Wuppertal, Germany,1 and
Institute of Medical Microbiology, University of Zürich,
CH-8028 Zürich, Switzerland2
Received 18 October 1999/Accepted 3 February 2000
 |
ABSTRACT |
The FemAB-like factors Lif and Epr confer resistance to
glycylglycine endopeptidases lysostaphin and Ale-1, respectively, by
incorporating serine residues into the staphylococcal peptidoglycan interpeptide bridges specifically at positions 3 and 5. This required the presence of FemA and/or FemB, in contrast to earlier postulations.
 |
TEXT |
Glycylglycine endopeptidases are
staphylolytic enzymes that cleave the pentaglycine interpeptide bridges
of the staphylococcal peptidoglycan. Staphylococcus simulans
biovar staphylolyticus, which produces lysostaphin, and
Staphylococcus capitis, which produces Ale-1, protect
themselves from their endopeptidases by the corresponding lysostaphin
immunity factor Lif (1, 10) or the endopeptidase resistance
factor Epr, respectively (9). Resistance is due to the
integration of serine in place of glycine residues in the peptidoglycan
pentaglycine interpeptide bridge (1, 9, 10). Pentaglycine
interpeptide bridge formation in Staphylococcus aureus
depends on at least three factors, FmhB (7), FemA (5,
8), and FemB (4), which are needed for the addition of
the first, the second and the third, and the fourth and the fifth
glycines, respectively. Lif and Epr show up to 41% identity to FemA
and FemB, suggesting that they may be catalyzing serine incorporation,
and Lif was suggested to complement FemB (11). Here, we
determined the positions of serine residues within the interpeptide
bridge in a wild-type strain and different femAB mutants
complemented with lif or epr and found a high
specificity of Lif and Epr for serine incorporation at positions 3 and
5. Neither Lif nor Epr alone was able to extend the shortened cross bridges in the femAB mutants by the addition of serine
residues, suggesting that both proteins depend on FemA and FemB for activity.
Muropeptide profile of wild-type and femAB mutants
expressing lif.
Upon expression of lif from
plasmid pCXlif (10), the amino acid fraction of the
peptidoglycan in parent strain BB270 (NCTC 8325, mec) and in
the corresponding femB mutant BB815 (mec,
2006femB::Tn551) (4)
showed an increased serine content, whereas that of the femA
mutant UK17 (mec, ochre mutation in femA)
(3) and the femAB null mutant AS145
(mec,
femAB::tetK)
(8) was not altered (11). The resulting
muropeptide patterns of BB270/pCXlif and BB815/pCXlif (11)
showed additional peaks in the monomeric and dimeric fractions (Fig. 1a
and b) when compared to the muropeptide profiles of the parent strains BB270 and BB815 (formerly UT43-2) determined earlier (5, 8). The main monomeric peaks of the two strains were collected and desalted as described (7),
and their amino acid sequence was analyzed by automated Edman
degradation (2). Since the major monomeric peak M4 could not
be separated from the novel peak S1 (BB270/pCXlif) (Fig. 1a), the amino
acid sequence of the isolated muropeptides revealed a mixture of the normal peptide with five glycine residues (M4; ~90%) and the peptide Gly-Gly-Ser-Gly-Ser (S1; ~10%). Furthermore, minor amounts
of the sequence Gly-Gly-Ser-Gly-Gly could be detected. Consistent with the shortened interpeptide bridge in the femB mutant,
the major monomeric peak M3 present in strain BB815/pCXlif (Fig. 1b) contained ~40% Gly-Gly-Gly (M3) and ~60% Gly-Gly-Ser (S2)
sequences. The retention times of muropeptides containing three glycine
residues and muropeptides containing one serine and two glycine
residues were nearly identical under the high-performance liquid
chromatography conditions used. Since the peaks designated S in Fig. 1a
and b were absent in the corresponding isogenic parent strains, it is likely that these muropeptides were also modified by serine-containing interpeptide bridges. Their amino acid composition could not be determined due to their low abundance. In contrast to the wild-type and
the femB mutant described above, expression of
lif did not alter the muropeptide pattern of strains AS145
and UK17, and the major monomeric peaks revealed only monoglycine side
chains as described earlier for femAB mutants (data not
shown). No serine residues were found in these two strains by amino
acid analysis.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
Muropeptide profile of the monomeric and dimeric
fractions of S. aureus BB270/pCXlif (a) and S. aureus BB815/pCXlif (b), BB270/pTSF6 (c), and BB815/pTSF6 (d).
Muropeptides were prepared as previously described (8).
Peaks were identified by comparison with the known profile of the
parent strains (4, 8). Novel peaks, not found in the
isogenic parental strains, are boxed. S, peaks that were not analyzed;
S1 to S6, peaks that could be isolated and were analyzed by Edman
degradation. M, P, and Pn stand for monomer disaccharide, stem
pentapeptide, and stem pentapeptide in which Gln was replaced with Glu,
respectively. M1, MP; M2, MP-Gly; M3, MP-Gly3; M4,
MP-Gly5; M8, MPn-Gly3; M9, mixture of
Mpn-Gly5 and MP-Ala; and M10, MP-(Gly4Ala).
Peptides marked by asterisks are probably degradation products produced
by endopeptidases and include the following: M2*,
MT-(Gly2), a total of two glycines substituted at two
possible sites, either Lys in position 3 or Ala in position 4 of the
stem tetrapeptide; M4*, MT-(Gly4); and M6*,
MT-(Gly6). Dimer muropeptides include the following: D3,
dimer of M4, and D4, dimer from M3 and M4, and D7, dimer of M3. D2* is
a degradation product containing two M4* units. The structure of the S
peptides, containing serine residues, is described in the text.
|
|
Muropeptide profile of wild-type and femAB mutants
expressing epr.
Similar to Lif, Epr was shown to increase
the serine content of the peptidoglycan (9). When plasmid
pTSF6 containing epr under the control of its own promoter
(9) was introduced into BB270, the serine content increased
compared to strain BB270 carrying the control plasmid pGC2 (Table
1). Likewise, the amount of serine increased in the femB mutant BB815/pTSF6 expressing
epr. However, only negligible amounts of serine could be
detected in the femAB double mutant AS145 carrying pTSF6
(Table 1).
The muropeptide profiles of strain BB270/pTSF6 and femB
mutant BB815/pTSF6 expressing epr showed additional peaks
(Fig. 1c and d) compared to the known muropeptide patterns of BB270 and BB815 (5, 7, 8). In addition to M4, a second major peak (S1)
with a slightly increased retention time was found in BB270/pTSF6. The
composition of the interpeptide side chain of peak S1 revealed by Edman
degradation the following sequences: Gly-Gly-Ser-Gly-Gly (~55%) and
Gly-Gly-Ser-Gly-Ser (~45%). Instead of the one major peak of control
strain BB270 (8), the dimeric fraction of strain BB270/pTSF6
contained three major peaks (Fig. 1c). Analysis of the amino acid
sequence of the interpeptide side chains of all three peaks revealed
the same amino acid sequences as in the monomeric peak S1 with
serine incorporated in position three or in positions three and five of
the cross bridge (Table 2). Overlapping
of the three dimeric peaks S3, S4, and S5 prevented isolation of pure
peaks. We found two muropeptide species in each of the peaks, namely
Gly-Gly-Ser-Gly-Gly and Gly-Gly-Ser-Gly-Ser (Table 2). Considering the
cross contamination, the different relative amounts suggested that S3
contains as main species dimers of Gly-Gly-Ser-Gly-Gly, whereas S4
contains both Gly-Gly-Ser-Gly-Gly and Gly-Gly-Ser-Gly-Ser, and S5,
though contaminated with S4, mainly represents dimers with
Gly-Gly-Ser-Gly-Ser bridges.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Amino acid composition of the interpeptide side chains of
the main dimeric muropeptides S3, S4, and S5 found in
BB270/pTSF6a
|
|
The monomeric muropeptide pattern of femB mutant BB815
complemented with epr revealed one major peak containing
58% triglycine cross bridges (M3), typical for a femB
mutant (4), and, similar to BB815/pCXlif, cross bridges with
the sequence Gly-Gly-Ser (42%; S2). The two main dimeric peaks (Fig.
1d) consisted of triglycine cross bridges (D7) and Gly-Gly-Ser cross
bridges (S6).
In accordance with the only slightly increased amount of serine found
in the peptidoglycan isolated from the femA mutant strain AS145/pTSF6 (Table 1) or UK17/pTSF6 (data not shown), only one minor
novel peak was found in the monomeric muropeptide fraction of
AS145/pTSF6, which could not be isolated in sufficient amounts for
Edman degradation but which is likely to be substituted by a serine
residue (data not shown).
Conclusions.
We could show that expression of Lif or Epr in
S. aureus led to the incorporation of serine residues
specifically in positions 3 and 5 of the interpeptide side chain. The
resulting alternating sequence of glycine and serine residues protects
the peptidoglycan from glycylglycine endopeptidases, which are unable
to hydrolyze glycylserine and serylglycine peptide bonds
(6). It is important to note that the detailed muropeptide
analysis revealed that neither Lif nor Epr extended the interpeptide
bridge. This is in contrast to the earlier postulation, based solely on
the total amino acid composition of the peptidoglycan, that Lif
complements FemB (11). The observation that the overall
cross-linkage degree was not changed in the femAB mutant
strains compared to their isogenic parental strains upon expression of
lif or epr (data not shown) made it additionally
unlikely that an increased amount of extended interpeptide bridges was
present in the highly cross-linked peptidoglycan fraction. Thus, it
seems that Lif requires the function of FemA and/or FemB for the
incorporation of serine to the existing interpeptide cross bridge and
that this function cannot be catalyzed by Lif or Epr alone. This is in
striking contrast to the glycyl-glycine elongation of the side chain by
FemA and FemB in S. aureus, despite the high sequence
identities of FemA and FemB with Lif and Epr. The fact that the serine
incorporation was dependent on the presence of either FemA and/or FemB
suggests possible protein interactions between FemA, FemB, and Lif or
Epr. There appear to be qualitative differences between Lif and Epr,
suggesting a more efficient Ser incorporation by Epr than by Lif.
However, we must take into account that Epr was expressed here from a
high-copy-number plasmid and from its own promoter, whereas Lif was
under the control of a xylose-inducible promoter in a vector with a
lower copy number. Compared to FemA and FemB, the function of Lif and
Epr seems to be different with regard to (i) serine instead of glycine
incorporation, (ii) the site specificity of the positions of the
incorporated serine residues, and (iii) the inability to attach
additional amino acids to the peptide cross bridge on their own.
 |
ACKNOWLEDGMENTS |
We thank K. Servan and M. Loriguillo for technical
assistance, M. Sugai for providing plasmid pTSF6, and G. Thumm for
providing plasmid pCXlif.
This study was supported by Swiss National Science Foundation grant
31.522239.97.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Medical Microbiology, University of Zürich, Gloriastr. 32, Postfach, CH-8028 Zürich, Switzerland. Phone: 41 1 634 26 50. Fax: 41 1 634 49 06. E-mail: bberger{at}immv.unizh.ch.
 |
REFERENCES |
| 1.
|
Dehart, H. P.,
H. E. Heath,
L. S. Heath,
P. A. Leblanc, and G. L. Sloan.
1995.
The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus.
Appl. Environ. Microbiol.
61:1475-1479[Abstract].
|
| 2.
|
Edman, P., and G. Begg.
1967.
A protein sequenator.
Eur. J. Biochem.
1:80-91[Medline].
|
| 3.
|
Ehlert, K.,
W. Schröder, and H. Labischinski.
1997.
Specificities of FemA and FemB for different glycine residues FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation.
J. Bacteriol.
179:7573-7576[Abstract/Free Full Text].
|
| 4.
|
Henze, U.,
T. Sidow,
J. Wecke,
H. Labischinski, and B. Berger-Bächi.
1993.
Influence of femB on methicillin resistance and peptidoglycan metabolism in Staphylococcus aureus.
J. Bacteriol.
175:1612-1620[Abstract/Free Full Text].
|
| 5.
|
Kopp, U.,
M. Roos,
J. Wecke, and H. Labischinski.
1996.
Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target?
Microb. Drug Resist.
2:29-41[Medline].
|
| 6.
|
Robinson, J. M.,
J. K. Hardman, and G. L. Sloan.
1979.
Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus.
J. Bacteriol.
137:1158-1164[Abstract/Free Full Text].
|
| 7.
|
Rohrer, S.,
K. Ehlert,
M. Tschierske,
H. Labischinski, and B. Berger-Bächi.
1999.
The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation.
Proc. Natl. Acad. Sci. USA
96:9351-9356[Abstract/Free Full Text].
|
| 8.
|
Strandén, A. M.,
K. Ehlert,
H. Labischinski, and B. Berger-Bächi.
1997.
Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus.
J. Bacteriol.
179:9-16[Abstract/Free Full Text].
|
| 9.
|
Sugai, M.,
T. Fujiwara,
K. Ohta,
H. Komatsuzawa,
M. Ohara, and H. Suginaka.
1997.
epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus.
J. Bacteriol.
179:4311-4318[Abstract/Free Full Text].
|
| 10.
|
Thumm, G., and F. Götz.
1997.
Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus.
Mol. Microbiol.
23:1251-1265[CrossRef][Medline].
|
| 11.
|
Tschierske, M.,
K. Ehlert,
A. M. Strandén, and B. Berger-Bächi.
1997.
Lif, the lysostaphin immunity factor, complements FemB in staphylococcal peptidoglycan interpeptide bridge formation.
FEMS Microbiol. Lett.
153:261-264[CrossRef][Medline].
|
Journal of Bacteriology, May 2000, p. 2635-2638, Vol. 182, No. 9
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kusuma, C., Jadanova, A., Chanturiya, T., Kokai-Kun, J. F.
(2007). Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo. Antimicrob. Agents Chemother.
51: 475-482
[Abstract]
[Full Text]
-
Lu, J. Z., Fujiwara, T., Komatsuzawa, H., Sugai, M., Sakon, J.
(2006). Cell Wall-targeting Domain of Glycylglycine Endopeptidase Distinguishes among Peptidoglycan Cross-bridges. J. Biol. Chem.
281: 549-558
[Abstract]
[Full Text]
-
Koehl, J. L., Muthaiyan, A., Jayaswal, R. K., Ehlert, K., Labischinski, H., Wilkinson, B. J.
(2004). Cell Wall Composition and Decreased Autolytic Activity and Lysostaphin Susceptibility of Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother.
48: 3749-3757
[Abstract]
[Full Text]
-
Rohrer, S., Berger-Bachi, B.
(2003). Application of a bacterial two-hybrid system for the analysis of protein-protein interactions between FemABX family proteins. Microbiology
149: 2733-2738
[Abstract]
[Full Text]
-
Rohrer, S., Berger-Bachi, B.
(2003). FemABX Peptidyl Transferases: a Link between Branched-Chain Cell Wall Peptide Formation and {beta}-Lactam Resistance in Gram-Positive Cocci. Antimicrob. Agents Chemother.
47: 837-846
[Full Text]
-
Goffin, C., Ghuysen, J.-M.
(2002). Biochemistry and Comparative Genomics of SxxK Superfamily Acyltransferases Offer a Clue to the Mycobacterial Paradox: Presence of Penicillin-Susceptible Target Proteins versus Lack of Efficiency of Penicillin as Therapeutic Agent. Microbiol. Mol. Biol. Rev.
66: 702-738
[Abstract]
[Full Text]
-
Reinscheid, D. J., Stosser, C., Ehlert, K., Jack, R. W., Moller, K., Eikmanns, B. J., Chhatwal, G. S.
(2002). Influence of proteins Bsp and FemH on cell shape and peptidoglycan composition in group B streptococcus. Microbiology
148: 3245-3254
[Abstract]
[Full Text]
-
Kiri, N., Archer, G., Climo, M. W.
(2002). Combinations of Lysostaphin with {beta}-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother.
46: 2017-2020
[Abstract]
[Full Text]
-
Climo, M. W., Ehlert, K., Archer, G. L.
(2001). Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
45: 1431-1437
[Abstract]
[Full Text]